Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316801 | 1.00 | NAMPT (0.42) | NAMPTHRH3KCNH2CYP2D6KDM4E | |
| SCHEMBL18390493 | 0.88 | NAMPT (0.51) | NAMPTHRH3KCNH2CYP2D6KDM4E | |
| SCHEMBL29316808 | 0.86 | HSD11B1 (0.45) | HRH3KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL26706122 | 0.86 | HSD11B1 (0.45) | HRH3KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL26746728 | 0.86 | HSD11B1 (0.45) | HRH3KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL29330578 | 0.86 | NAMPT (0.42) | NAMPTHRH3KCNH2CYP2D6KDM4E | |
| SCHEMBL26746721 | 0.84 | HSD11B1 (0.46) | NAMPTKDM4ETPSAB1TPSD1TPSG1 | |
| SCHEMBL26746716 | 0.84 | TPSAB1 (0.44) | HRH3KCNH2CYP2D6ALDH1A1TPSAB1 | |
| SCHEMBL26742027 | 0.84 | TPSAB1 (0.44) | HRH3KCNH2CYP2D6ALDH1A1TPSAB1 | |
| SCHEMBL25443839 | 0.83 | HRH3 (0.48) | NAMPTHRH3KCNH2CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | NAMPT 4770/4885HRH3 4026/4885KCNH2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.